NasdaqGM:FLGT

Exagen Inc. Appoints Paul Kim to Board of Directors

Retrieved on: 
Monday, July 24, 2023
Learning, University, COVID-19, XGN, Certified Public Accountant, Accounting, Genetics, SAN, Autoimmune disease, Berkeley, Growth, Management, Lipotriches exagens

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023.

Key Points: 
  • SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023.
  • Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (Nasdaq: FLGT), a full-service genomic testing company built around a foundational technology platform.
  • “We are thrilled to welcome Paul to our Board of Directors at Exagen.
  • “I look forward to learning from his 30 plus years of leadership in business.”
    “I am delighted to join the Board of Directors at Exagen,” said Paul Kim.

CONTINUED INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGT

Retrieved on: 
Wednesday, January 18, 2023
News, Genetics, U.S. Department of Justice Office of Legislative Affairs, Stark Law, Anti-Kickback Statute, Privacy Office of the U.S. Department of Homeland Security, Remuneration, Justice, Battle of Saint-Fulgent, Stark, Disclosure, Law, Pharmaceutical industry

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors of its continued investigation of certain directors and officers of Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders.

Key Points: 
  • NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors of its continued investigation of certain directors and officers of Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders.
  • If you are a Fulgent shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or [email protected] .
  • If you are a Fulgent shareholder, you may have legal claims against Fulgent’s directors and officers.
  • If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or [email protected] .

FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, January 14, 2023
News, Genetics, U.S. Department of Justice Office of Legislative Affairs, Anti-Kickback Statute, Privacy Office of the U.S. Department of Homeland Security, Remuneration, Justice, Telephone, Stark, Disclosure, P.C, Battle of Saint-Fulgent

NEW YORK, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (NASDAQ: FLGT) on behalf of long-term stockholders following a class action complaint that was filed against Fulgent on September 20, 2022 with a Class Period from March 22, 2019 to August 4, 2022.

Key Points: 
  • NEW YORK, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (NASDAQ: FLGT) on behalf of long-term stockholders following a class action complaint that was filed against Fulgent on September 20, 2022 with a Class Period from March 22, 2019 to August 4, 2022.
  • Our investigation concerns whether the board of directors of Fulgent have breached their fiduciary duties to the company.
  • On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC was conducting an investigation into certain of Fulgent’s reports filed with the SEC from 2018 through the first quarter 2020.
  • There is no cost or obligation to you.

Barrack, Rodos & Bacine (BR&B) Is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) For Potential Investor Claims

Retrieved on: 
Tuesday, December 27, 2022
Linda, McKesson Corporation, Fraud, MCI Inc., BR, Acquisition, Cendant, AIG, Genetics, Battle of Saint-Fulgent, History

PHILADELPHIA, Dec. 27, 2022 (GLOBE NEWSWIRE) --  Barrack, Rodos & Bacine (BR&B) is investigating Fulgent Genetics Inc. based on issues arising from its recent acquisitions, including the acquisition of Fulgent Pharma LLC, a wholly owned subsidiary of Fulgent Pharma Holdings, which itself is wholly-owned by Ming Hsieh (Fulgent Genetic’s President and CEO) and a related Hsieh Trust that he controls.

Key Points: 
  • PHILADELPHIA, Dec. 27, 2022 (GLOBE NEWSWIRE) --  Barrack, Rodos & Bacine (BR&B) is investigating Fulgent Genetics Inc. based on issues arising from its recent acquisitions, including the acquisition of Fulgent Pharma LLC, a wholly owned subsidiary of Fulgent Pharma Holdings, which itself is wholly-owned by Ming Hsieh (Fulgent Genetic’s President and CEO) and a related Hsieh Trust that he controls.
  • BR&B is also investigating the recent resignations of several members of Fulgent Genetics’ Board and certain stock transactions made by CEO Hsieh over the past few years.
  • If you are a Fulgent Genetics shareholder, you are encouraged to contact Mark Stein or Linda Border at Barrack, Rodos & Bacine, at the toll-free number 877-386-3304, or via email at [email protected] or [email protected] , to learn more about the firm’s investigation and your legal rights and options.
  • The firm's largest recoveries on behalf of investors include $6.19 billion for WorldCom investors, $3.32 billion for Cendant investors, $1.05 billion for McKesson investors, and $970.5 million for AIG investors.

DEADLINE ALERT for FLGT, YSG, BCS, and OLO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, November 21, 2022
Law, Stark Law, Genetics, IPO, Defendant, Battle of Saint-Fulgent, Anti-Kickback Statute, Suite, Investment, Remuneration, Security (finance), Mail, Holding company, Risk management, Barclays

LOS ANGELES, Nov. 21, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Nov. 21, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Fulgent Genetics, Inc. (FLGT)

Retrieved on: 
Sunday, November 20, 2022
COVID-19, COPY, Central District, Stark Law, U.S. Department of Justice Office of Legislative Affairs, LLP, Disclosure, Anti-Kickback Statute, Insurance, Health, Stark, Physician, Genetics, Patient, Lead, Reward, Battle of Saint-Fulgent, Office of Inspector General, U.S. Department of Health and Human Services, District court, News, Medicare, Justice, Genetic testing, Fraud, Remuneration, Private investigator, Pharmaceutical industry, Architecture

Kessler Topaz Meltzer & Check, LLP encourages Fulgent investors who have suffered significant losses to contact the firm directly to acquire more information.

Key Points: 
  • Kessler Topaz Meltzer & Check, LLP encourages Fulgent investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

FLGT 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Fulgent Genetics (FLGT) Investors with Significant Losses to Contact the Firm’s Attorneys Before Nov. 21st Deadline in Securities Class Action

Retrieved on: 
Saturday, November 19, 2022
SAN, Disclosure, Steve Berman (lawyer), Stark Law, Genetics, News, DOJ, Person, Fraud, Pharmaceutical industry, Tobacco, Battle of Saint-Fulgent

SAN FRANCISCO, Nov. 19, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Fulgent Genetics, Inc. (NASDAQ: FLGT) investors who suffered significant losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Nov. 19, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Fulgent Genetics, Inc. (NASDAQ: FLGT) investors who suffered significant losses to submit your losses now .
  • A securities fraud class action has been filed after Fulgent disclosed the DOJ and SEC are conducting investigations.
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) Securities Fraud Class Action:
    The litigation focuses on Fulgents previously claimed very strong and truly outstanding financial results.
  • If you invested in Fulgent and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .

FLGT DEADLINE ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Fulgent Genetics, Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action – FLGT

Retrieved on: 
Friday, November 18, 2022
Titan, Advertising, Health, Stark Law, Genetics, Class, I-Space (Chinese company), Federal, Court, Reward, Battle of Saint-Fulgent, Medicare, Anti-Kickback Statute, Remuneration, Insurance, Tobacco, Pharmaceutical industry

WHAT TO DO NEXT: To join the Fulgent Genetics class action, go to https://rosenlegal.com/submit-form/?case_id=8809 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Fulgent Genetics class action, go to https://rosenlegal.com/submit-form/?case_id=8809 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Lifshitz Law PLLC Announces Investigations of Kohls Corporation (NYSE: KSS), Sema4 Holdings Corporation (NASDAQ: SMFR), Palantir Technologies, Inc. (NYSE: PLTR), and Fulgent Genetics, Inc. (NASDAQ: FLGT)

Retrieved on: 
Friday, November 18, 2022
Growth, Disclosure, Telephone, Risk, Stark Law, Government, Hewlett, Complaint, Defendant, EPS, Advertising, Battle of Saint-Fulgent, Anti-Kickback Statute, Investment, Remuneration, Risk management, Mail, Pharmaceutical industry, Palantir Technologies, Kohl's

If you are an Kohls investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are an Kohls investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are a Sema4 investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of Palantir alleging that Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.